{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"240"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"346"},{"groupId":"OG001","value":"334"}],"units":"Participants"}],"description":"Assessed by Common Terminology Criteria for Adverse Events version 4.0. The number of patients experiencing a grade 3 or greater adverse event (AE) regardless of attribution will be reported.","groups":[{"description":"Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3 of each cycle. Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, beginning in cycle 1 or 2. Treatment repeats every 14 days for up to 25 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI every 6 months for the first 2 years, then for years 3-5 or until evidence of relapse, whichever comes first. Patients may also undergo blood sample collection throughout the trial.\\> \\> Atezolizumab: Given IV\\>\n\n\\> Biospecimen Collection: Undergo blood sample collection\\>\n\n\\> Computed Tomography: Undergo CT\\>\n\n\\> Fluorouracil: Given IV\\>\n\n\\> Leucovorin Calcium: Given IV\\>\n\n\\> Magnetic Resonance Imaging: Undergo MRI\\>\n\n\\> Oxaliplatin: Given IV\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies","id":"OG000","title":"Arm I (Combination Chemotherapy, Atezolizumab)"},{"description":"Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3 of each cycle. Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI every 6 months for the first 2 years, then for years 3-5 or until evidence of relapse, whichever comes first. Patients may also undergo blood sample collection throughout the trial.\\>\n\n\\> Biospecimen Collection: Undergo blood sample collection\\>\n\n\\> Computed Tomography: Undergo CT\\>\n\n\\> Fluorouracil: Given IV\\>\n\n\\> Leucovorin Calcium: Given IV\\>\n\n\\> Magnetic Resonance Imaging: Undergo MRI\\>\n\n\\> Oxaliplatin: Given IV\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies","id":"OG001","title":"Arm II (Combination Chemotherapy)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only patients that received treatment were included in AE analysis","reportingStatus":"POSTED","timeFrame":"5 years","title":"Number of Patients Experiencing Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}